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FUNDING STEM CELL RESEARCH: THE
CONVERGENCE OF SCIENCE, RELIGION & POLITICS
IN THE FORMATION OF PUBLIC HEALTH POLICY
Edward A. Fallone*
Public health policy in the United States has long been
influenced by three factors: the imperfect and evolving state of
scientific knowledge about human biology, the far less
changeable status of religious doctrine concerning the human
body, and the constant compromises and accommodations made
by elected officials in an attempt to garner the support of
divergent political interest groups. Scholars have even
developed a new term to describe this field of inquiry: "public
bioethics." The current debate over the funding of stem cell
research, in particular human embryonic stem cell (hESC)
research, is but the most recent convergence of these three
influences on public policy. Advocates of federal and state
government funding of embryonic stem cell research argue that
our democratic government should foster and promote the path
of discovery, especially where that inquiry focuses on the causes
and cures of disease. Opponents of federal and state funding
argue that our democratic government should reflect the moral
values of our population, a portion of which object to embryonic
* Associate Professor, Marquette University Law School. In my private
life, I am the president of a nonprofit organization that advocates in
support of all forms of stem cell research. I would like to thank
Professor Aaron D. Levine for his comments and suggestions. I would
also like to thank my daughter Emma and my son Andrew, both of
whom inspire me every day.
1. 0. Carter Snead, Science, Public Bioethics, and the Problem of Integration, 43
U.C. DAVIs L. REV. 1529, 1532 (2010) (defining "public bioethics" as the "the
governance of the practice of medicine, biotechnology, and biomedical research in
the name of ethical goods").
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stem cell research on religious grounds. 2
Differing conceptions of knowledge contribute to this
debate. Scientific knowledge follows an uncertain path, and
those who are engaged in scientific research assume that
complete and final knowledge is an unattainable goal.3 New
discoveries are episodic and tentative. While impressive
additions to the universe of human knowledge have been made
since 1998, when Dr. Jamie Thomson successfully isolated
human embryonic stem cells for the first time,4 today there still
remains much that we do not understand about cell biology.
Religious doctrine, in contrast, rests upon the assertion that
certain truths are unassailable and are not subject to change
regardless of the results of scientific inquiry.' The doctrines of
the Catholic Church, in particular, historically have opposed
both contraception and abortion. These doctrines are based
upon Church teachings in regards to human sexuality and
reproduction that have evolved little since the time of Saint
Augustine .6
Some observers assert that it is inevitable for scientific and
2. An October 2010 Harris Interactive poll found strong support for
embryonic stem cell research among the public. According to the poll, 73% of
respondents support stem cell research "as long as the parents of the embryo give
their permission, and the embryo would otherwise be destroyed." Among the
poll's findings: 58% of Republicans support stem cell research (with 24% of
Republicans opposed), while the research is supported by 69% of Catholics and 58%
of born-again Christians. In contrast, the poll found that embryonic stem cell
research is opposed by 16% of Catholics and 22% of born-again Christians. See
Amanda Gardner, Most Americans Back Embryonic Stem Cell Research: Poll,
BLOOMBERG BUSINESSWEEK (Oct. 7, 2010), http://www.businessweek.com/lifestyle
/content/healthday/644026.html.
3. BERTRAND RUSSELL, RELIGION AND SCIENCE 14 (Oxford University Press
1997) (1935).
4. James A. Thomson et al., Embryonic Stem Cell Lines Derived from Human
Blastocysts, 282 SCIENCE 1145, 1145 (1998).
5. See RUSSELL, supra note 3, at 13-17.
6. See generally JOHN T. NOONAN, JR., CONTRACEPTION: A HISTORY OF ITS
TREATMENT BY THE CATHOLIC THEOLOGIANS AND CANONISTS (1965). There is,
however, a vigorous debate concerning the extent to which Catholic doctrine on
these matters has in fact changed in meaningful ways over the centuries. See
generally Christine E. Gudorf, Contraception and Abortion in Roman Catholicism, in
SACRED RIGHTS: THE CASE FOR CONTRACEPTION AND ABORTION IN WORLD
RELIGIONS 55 (Daniel C. Maguire ed., 2003).
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religious viewpoints to come into direct conflict.' Others believe
that it is possible for the government to craft policies that
advance both scientific and religious perspectives.8 Indeed, the
very concept of public bioethics as a field of inquiry assumes
that it is both necessary and possible for government
policymakers to accommodate these two differing attitudes
towards the acquisition of knowledge.'
The convergence of science, religion and politics in the
health care context has engendered controversy in the past. In
the 1980s, a newly identified communicable disease known as
Acquired Immune Deficiency Syndrome (AIDS) gave rise to
fears of an epidemic and prompted calls for a public health
response. Medical researchers criticized the federal government
for being slow to develop and adopt a national AIDS strategy.
In addition, many scientists questioned Congress' decision to
fund research for a vaccine through supplemental
appropriations rather than by increases to the budget of the
National Institutes of Health (NIH).10
The early (and incomplete) scientific understanding of the
disease led some persons to conclude that the illness was
primarily spread through immoral conduct. Other segments of
the public objected to using tax dollars to fund public education
and prevention programs that advocated the use of condoms.
7. See RUSSELL, supra note 3, at 13-17.
8. See GARRY WILLS, HEAD AND HEART: A HISTORY OF CHRISTIANITY IN
AMERICA 547-52 (2007).
9. See Snead, supra note 1, at 1602 (concluding that the question of federally
funding embryonic stem cell research "should be decided by politically accountable
public officials, applying the humanistic concepts of moral reasoning").
10. Much of the controversy over the appropriate role of the federal
government in responding to the AIDS crisis played out as a funding debate:
From June 1981 to June 1982, a period generally considered to be the first
twelve months of the epidemic, the Centers for Disease Control and
Prevention (CDC) spent $1 million on AIDS, compared with $9 million in
response to the much smaller problem of Legionnaires' disease. In late
1982, Congress allocated $2.6 million to be targeted for the CDC's AIDS
research, but the Reagan administration claimed that the CDC did not
need the money and opposed any congressional supplemental
appropriations designed to fund federal governmental AIDS policy efforts.
ENCYCLOPEDIA OF AIDS: A SOCIAL, POLITICAL, CULTURAL, AND SCIENTIFIC RECORD
OF THE HIV EPIDEMIC 164 (Raymond A. Smith, ed., Penguin Reference 2001) (1998).
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Meanwhile, on the other end of the political spectrum, gay rights
advocates objected to the utilization of traditional public health
powers, such as quarantine, as a means of combating the spread
of AIDS. Liberal groups feared that these "archaic" police
powers would inevitably be used to target homosexuals in
general rather than the affected population." As a result, the
public health response to the AIDS crisis was hampered by the
need to accommodate religious and political interest groups.
The funding of medical researchl 2 using stem cells provides
a contemporary opportunity to examine the intersection of
science, religion and politics in the formation of public health
policy. In Section I, this article reviews the science of stem cell
research. Section II addresses religious and ethical perspectives
relating to stem cell research. In Section III, the current funding
landscape for stem cell research is examined. Interest group
litigation seeking to influence federal and state funding policies
is discussed in Section IV. Finally, in Section V, this article
articulates two neutral principles that should guide
policymakers in future situations where public health decisions
implicate science, religion and politics.
THE SCIENCE OF STEM CELL RESEARCH
A BRIEF HISTORY OF REGENERATIVE MEDICINE
Researchers and their advocates believe that stem cell
research has the potential to greatly alleviate human suffering.
11. See generally Edward A. Fallone, Preserving the Public Health: A Proposal to
Quarantine Recalcitrant AIDS Carriers, 68 B.U. L. REV. 441 (1988).
12. Medical research takes place in three stages. Basic medical research
(sometimes called the "discovery phase") typically takes place at academic
institutions and is usually funded by the state and federal governments rather than
by for-profit corporations. Preclinical research, the second stage, focuses on
applications that build off of basic research discoveries and on "proof of concept"
testing. Academic institutions engage in this second stage of research, along with
biotech and pharmaceutical companies seeking to develop patentable technologies.
The third stage of medical research is clinical research. Clinical research is
performed in order to verify the safety and efficacy of treatments on human
patients, and it is typically conducted by both academic institutions and by large
corporations developing a marketable product.
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Numerous diseases and chronic medical conditions, including
Diabetes, ALS, Multiple Sclerosis, Parkinson's Disease,
Alzheimer's, and spinal cord injury, may be susceptible to
treatment or even cures using stem cells. Many of these diseases
disproportionately affect the elderly, an important factor in
consideration of the rapidly aging American population.13
Supporters argue that the development of therapies for chronic
health conditions would also be beneficial to the economy,
because costs associated with the treatment of chronic disease
are a significant contributor to the steady rise in health care
spending in our nation. However, stem cell research is merely
the latest stage in the long and often controversial history of
regenerative medicine.14
For hundreds of years, medical research has sought
treatments for human tissue and organs that have been
damaged, whether by accident, genetic defect, or degenerative
disease. 5 One consistent focus of this research has been the
possibility of replacing the non-functioning body part with a
healthy alternative. The earliest blood transfusions in the
eighteenth century became the template for the first organ
transplants - the replacement of damaged or diseased organs
with healthy organs from a donor. As the transplantation
techniques advanced over the decades, transplants involving
kidneys, hearts, lungs and other types of organs have become
commonplace.
One drawback to organ transplantation is the need to
suppress the recipient's immune system in order to prevent the
rejection of foreign tissue. However, a far more significant
drawback has proven to be the limited supply of donated organs
13. See Cynthia M. A. Geppert, Stem Cell Research, in ENCYCLOPEDIA OF AGING
AND PUBLIC HEALTH 760, 760-61 (Sana Loue & Martha Sajatovic eds., 2008) ("Stem
cell research offers enormous potential to improve the quality of life of older people
and even to extend the life span.").
14. The term "regenerative medicine" applies to treatments intended to repair
damaged or diseased tissues and organs in the human body, whether via tissue
engineering, stem cell therapy, the use of mechanical devices or other techniques.
15. "Tissue" refers to specialized human cells that perform a specific bodily
function. "Organs" refer to body parts containing multiple related types of tissue.
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for transplantation. In response to this shortage, researchers
have explored the use of mechanical devices that function as
artificial organs and, in certain instances, the use of organs
obtained from animal sources. These developments led to
objections by some to the introduction of non-human material
into the recipient's body, on religious grounds. Nonetheless, a
majority of the public favored the use of these alternative
sources of organs so long as ethical guidelines were followed. 16
Neither mechanical nor animal organs are an exact
substitute for the healthy human organs that they are designed
to replace, however. In addition, despite recent advances in
nanotechnology, researchers still struggle to create machines
that can perform biological functions at a cellular level.
Therefore, the finite supply of donated human organs continues
to be the primary limitation on the use of transplantation as a
treatment for disease and chronic injury.
In the 1970s, significant progress was made in the field of
recombinant DNA. Researchers inserted strands of human
DNA into bacteria in order to manufacture proteins and artificial
hormones that exactly mimic their parallels in the human body.
An entire new branch of the pharmaceutical industry developed
in order to produce drugs designed to trigger natural responses
within the patient's body.17  These advances in recombinant
DNA were initially controversial, and some persons viewed the
combination of human DNA with a bacterial host as evidence of
a scientific community run amuck.18
16. For a discussion of religious perspectives on the bodily incorporation of
mechanical devices, see generally Courtney S. Campbell et al., The Bodily
Incorporation of Mechanical Devices: Ethical and Religious Issues (Part 2), 16 CAMBRIDGE
Q. HEALTHCARE ETHICS 268 (2007).
17. For example, diabetics today inject artificial insulin that is genetically
identical to human insulin. The patient must still inject the artificial insulin several
times a day, so it is not the equivalent of replacing the patient's damaged pancreas.
Nonetheless, the genetically manufactured insulin is considered superior to insulin
harvested from slaughtered pigs, which was the previous source of injectable
insulin. Similarly, drugs created using recombinant DNA can be used to trigger an
increase in the body's red blood cell production during chemotherapy.
18. See ROGER SHATTUCK, FORBIDDEN KNOWLEDGE: FROM PROMETHEUS TO
PORNOGRAPHY 186-195 (1996).
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Stem cell research is the most recent stage in the historical
progress of regenerative medicine. Stem cell research focuses on
the process of human biology at a cellular level, and is therefore
one way that researchers hope to learn how to repair or replace
human organs and tissues. The ultimate goal of this science is to
create new adult human cells, either by growing them from
undifferentiated stem cell lines or by transforming one type of
adult cell directly into another type. One potential use of these
newly created cells is to test experimental drugs on human
tissue without having to conduct clinical trials on human
subjects. However, a second potential use, which is of particular
interest to millions of Americans with chronic medical
conditions, is to create a new source of organs and tissues that
can be used for transplantation.
STEM CELL RESEARCH: A VARIETY OF APPROACHES
Stem cells are "unspecialized" cells that can generate
healthy new cells, tissues, and organs. They are the master cells
of the human body and, when isolated outside of the body, they
can be manipulated to transform into more specialized cells that
perform specific bodily functions. A stem cell "line" is formed
by extracting stem cells from their source and placing them in a
growth culture in a petri dish. The stem cells are then induced
to self-replicate, generating a colony of stem cells that
continually replaces itself. Researchers then apply factors to the
stem cell line that cause the stem cells to transform into
specialized adult cells.
Adult Stem Cell Research
After birth, small amounts of stem cells remain in many
mature human organs, where they continue to create specialized
cells that replace cells that have become damaged or worn out.
Researchers have long known that it is possible to use these
adult stem cells in order to generate different types of
specialized replacement cells. Adult stem cells are characterized
2011] 253
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as "multipotent,"19 meaning that they can be transformed into a
limited number of specialized cell types. Replacement cells
created using adult stem cells are usually closely related to the
types of cells that reside in the tissue where the adult stem cells
were located. In other words, adult stem cells derived from
blood-producing bone marrow can be used to produce different
kinds of specialized blood cells, but it is unclear whether they
can be used to produce nerve or muscle cells.
Embryonic Stem Cell Research
After the union of sperm and egg, the fertilized egg
undergoes several stages of development. The fertilized egg
divides into two cells, then four, eight, and so forth, until it
reaches a stage where it is called a morula ("berry" in Latin).2 0
Approximately four days after fertilization, this solid mass of
cells begins to transform from a compressed morula into a
hollowed-out ball called a blastocyst.2 1 The blastocyst is about
the size of the period at the end of this sentence, and its interior
contains a thin ridge of cells. 22 These are the embryonic stem
cells, and they can be extracted from the blastocyst and grown in
culture. Embryonic stem cells are the progenitor cells that serve
as precursors of every cell type that will later be necessary for
human development.
Prior to extraction from the blastocyst, the embryonic stem
cells are "totipotent," meaning that they possess the ability to
develop into any of the three types of human tissue (endoderm,
mesoderm, or ectoderm) and also to develop into the placental
tissues needed for the blastocyst to implant in the uterus. 23 An
embryonic stem cell line is created by removing the embryonic
stem cells from the blastocyst and inducing them to reproduce in
19. See Ralph Dittman, Latest Developments in Stem Cell Research, THE
HUFFINGTON POST (Nov. 21, 2007, 6:10 PM), http://www.huffingtonpost.com/ralph-
dittman/1atest-developments-in-st b_73783.html?view=screen.
20. Id.
21. Id.
22. Id.
23. Id.
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a cultured petri dish. Once removed from the blastocyst, the
embryonic stem cells are "pluripotent," meaning that they have
the ability to develop into any of the 210 or so different cell types
of a human body24 but that they no longer possess the ability to
form placental tissues.
The extraction of the embryonic stem cells from the
blastocyst typically occurs between five and ten days after
fertilization.2 5 Extraction is performed during this early time
frame because, as the blastocyst continues to develop, the cells
become even more differentiated and specialized. Until about
day fourteen, the cell mass could be divided in two segments,
and it would result in two viable identical cell masses.
However, after day fourteen the cells become differentiated to
the point that, if one were to attempt to divide them, the entire
cell mass would arrest and stop developing. In addition, by day
fourteen the cells have become so specialized that they cease to
be pluripotent, but are merely multipotent instead.26
Self-perpetuating embryonic stem cell lines were first
successfully isolated from humans and cultured by Dr. James
Thomson at the University of Wisconsin in 1998.27 In the United
States, hESC research uses eggs that have been fertilized in vitro
and then donated for research purposes with the informed
consent of their donors. These eggs were not fertilized in a
woman's body, but rather were created at an in vitro fertility
clinic. They exist because the in vitro fertilization (IVF) process
24. Id.
25. Extraction of the stem cells from the blastocyst collapses the outer line of
cells and renders the blastocyst incapable of implantation in the uterine wall. It is
the destruction of the blastocyst at this stage that has engendered opposition to
hESC research. It should be noted that at this stage in the development of the
blastocyst, were it located in the human body, it would still be traveling through
the fallopian tubes and would not yet have reached the uterus. It is estimated that
fewer than one third of fertilized eggs successfully implant in the uterus during
human reproduction and proceed to develop to term. Instead, the majority of eggs
that are fertilized within the woman's body pass through the uterus or, after
implantation, spontaneously abort. Biologists do not consider conception to occur
until implantation in the womb. See HAROLD J. MOROWITZ & JAMES S. TREFIL, THE
FACTS OF LIFE: SCIENCE AND THE ABORTION CONTROVERSY 51 (1992).
26. See Dittman, supra note 19.
27. See Thomson et al., supra note 4, at 1145.
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typically results in the creation of excess blastocysts, and if not
used for research purposes the majority of these fertilized eggs
would be destroyed. 28 Federal funding of hESC research is
currently limited to research using excess blastocysts obtained
from IVF clinics. In addition, federal dollars may only be used
to support research using pre-existing hESC lines and not for the
derivation of new hESC lines from blastocysts.
Induced Pluripotent Stem Cells (iPS cells)
In November 2007, both Dr. James Thomson of the
University of Wisconsin and a separate team under the direction
of Dr. Shinya Yamanaka in Japan announced that they had
discovered how to create cells that behave like embryonic stem
cells by adding a "cocktail" of four gene transcription factors to
an adult skin cell.2 9 This technique converts routine body cells,
or somatic cells, into pluripotent stem cells. In technical terms,
the technique "de-differentiates" the adult cell. These re-
programmed somatic cells are called "induced pluripotent stem
cells" or iPS cells.
The breakthrough involved using four factors - including
cancer genes - that were inserted into human adult skin cells
using retroviruses as a vehicle. These factors "re-programmed"
the skin cells with the result that they began to behave like
embryonic stem cells. These iPS cells appear to have a plasticity
similar to embryonic stem cells, although it is unknown whether
they are an exact equivalent. One potential advantage of using
stem cells created via the iPS technique is that there would be no
immune system issues should those cells be transplanted back
into the patient that donated the skin cells. Early concerns
expressed over the use of cancer genes and retroviruses to do the
28. A 2004 study found that eighty-four percent of fertility clinics routinely
destroyed unused blastocysts created for implantation. See Andrea D. Gurmankin
et al., Embryo Disposal Practices in IVF Clinics in the United States, 22 POL. & LIFE SC.
4, 6 (2004) (In a survey, 175 out of 208 IVF clinics reported that they had policies
permitting the disposal of excess embryos.).
29. See Kazutoshi Takahashi et al., Induction of Pluripotent Stem Cells from Adult
Human Fibroblasts by Defined Factors, 131 CELL 861, 868 (2007).
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reprogramming - the introduction of which might "switch on"
cancer genes already present within the body - were addressed
through the development of new methods of re-programming
which do not utilize cancer genes.
Direct Cell Re-Programming
The expanded knowledge of cell biology that has been
gained from stem cell research has also led to techniques that
transform one type of specialized adult cell directly into another
type of adult cell. Using this approach, researchers can side-step
the entire process of creating any stem cell lines. This process
has been labeled "direct reprogramming."
In 2008, Dr. Douglas Melton at the Harvard Stem Cell
Institute announced successful experiments in mice where he
transformed normal pancreas cells into more specialized insulin
producing cells.30  He achieved these results by using a
"cocktail" of three transcription factors to transform one type of
adult mouse cell directly into a different type of adult cell. This
advance allowed the creation of new adult mouse cells without
first creating a stem cell line. If this technique can be replicated
using human cells, it would also seem to avoid potential
problems with the extraction of adult stem cells or the rejection
of transplanted cells by the immune system. Similar to iPS
research, the initial direct re-programming results involved the
use of a virus as the vehicle for introducing the genes into the
cells. A non-viral approach needs to be developed to avoid the
risk that the virus will induce the growth of cancerous tumors.
Comparability and Equivalency Among Different Types of Stem
Cell Research
Because human embryonic stem cells are able to
differentiate into any cell type in the body, scientists believe that
they hold great promise - both as a source of replacement cells
30. See Qiao Zhou et al., In Vivo Reprogramming of Adult Pancreatic Exocrine Cells
to p-Cells, 455 NATURE 627, 630-31 (2008).
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for transplantation and for use in testing drug interactions in
human tissue. Their plasticity, and their durability as self-
sustaining cell lines that self-replicate over long periods of time,
are the primary advantages of embryonic stem cells. For
example, researchers have used embryonic stem cells to create
large quantities of red blood cells, raising the prospect that one
day blood drives may be unnecessary.3' In addition, because
embryonic stem cells have developed only once from their
embryonic state, tissue created using embryonic stem cells is
considered to be the closest equivalent to naturally occurring
human tissue. Immunosuppression issues remain one of the
primary concerns in regards to hESC research.
In contrast, adult stem cells extracted from the patient's
own body do not trigger an immune system response when
used to create specialized cells that are re-introduced into the
patient's body. However, there are currently several
disadvantages associated with the use of adult stem cells. First,
researchers have yet to find a collection of adult stem cells
throughout the body that can give rise to all of the various types
of cells and tissues present in the human body. In addition, in
some instances adult stem cells may be present in mature organs
but the extraction of these adult stem cells is difficult or
dangerous to the patient. This is currently the case with adult
stem cells located in the heart and the brain.
Second, adult stem cells are often present in only minute
quantities in mature tissues in the body.32 They can therefore be
difficult to isolate, purify and replicate in large quantities. This
is an important drawback, as large numbers of cells are likely to
be necessary for stem cell replacement therapies. In contrast,
hESC derived cells are relatively easy to grow in cultures and
can multiply perfectly for long periods of time.
Finally, it is still unclear whether adult stem cells contain
31. See Shi-Jiang Lu et al., Biologic Properties and Enucleation of Red Blood Cells
from Human Embryonic Stem Cells, 112 BLOOD 4475, 4475 (2008).
32. Stem Cell Information Frequently Asked Questions, NAT'L INSTS. HEALTH,
http://stemcells.nih.gov/info/faqs.asp (last updated Aug. 2, 2010).
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more DNA abnormalities than hESC cells. It is thought that
"sunlight, toxins, or errors in making more DNA copies during
the course of a [cell's] lifetime" may increase the incidence of
abnormalities among adult stem cells.33 While researchers may
eventually overcome some or all of the above limitations, adult
stem cells cannot currently be considered a complete substitute
for embryonic stem cells.
There are also uncertainties associated with the derivation
of iPS cell lines. For example, there is evidence that iPS cell lines
are less efficient than embryonic stem cell lines in self-
replicating, and that the tissue developed using iPS cell lines
differs in noticeable ways from tissue derived from hESC lines.34
In addition, the process of reversing an adult cell to its
embryonic state creates not only iPS cells but also non-iPS cell
colonies and "pseudo-iPS cells" that fail to regress completely.35
Therefore, it can be challenging for researchers to differentiate
among iPS cells sharing the same petri dish with potentially
cancerous cells. Scientists need to continue to work on the
purification techniques necessary to identify and isolate the true
iPS cells. There also remains considerable uncertainty
concerning the stability of iPS cells over time. Some researchers
believe that the re-programming process renders iPS cells less
stable than embryonic stem cells, and there are indications that
iPS cells are more prone to develop tumors than embryonic stem
cells.36 It is necessary to conduct equivalency studies comparing
iPS and embryonic stem cells in order to definitively answer
33. Id.
34. See Sergio Pistoi, Do We Still Need Human Embryonic Stem Cells?, INT'L SOC'Y
STEM CELL RESEARCH (Oct. 1, 2010), http://www.isscr.org/public/briefings
/human embryonicstemscells.html (citing studies).
35. Paul Knoepfler, Some Inconvenient Truths About iPS Cells, KNOEPFLER LAB
STEM CELL BLOG (Dec. 12, 2010, 4:41 PM), http://www.ipscell.com/home.php
?s=some-inconvenient-truths-about-ips-cells. There is also evidence that the
regressed cells retain a "memory" of their original state. Jose M. Polo et al., Cell
Type of Origin Influences the Molecular and Functional Properties of Mouse Induced
Pluripotent Stem Cells, 28 NATURE BIOTECHNOLOGY 848, 851 (2010).
36. See Louise C. Laurent et al., Dynamic Changes in the Copy Number of
Pluripotency and Cell Proliferation Genes in Human ESCs and iPSCs During
Reprogramming and Time in Culture, 8 CELL STEM CELL 106, 106-08 (2011).
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these questions, but in the meantime we simply don't know
whether cells created using iPS lines will function in an identical
manner as cells created using hESC lines over long periods of
time.
Another consideration in the comparison of iPS cell lines
and hESC lines is the cost associated with therapies. The
advantage of iPS cell lines is that they are derived using the
patient's own somatic cells, and therefore avoid the need for
immunosuppressant drugs.37 However, the disadvantage to the
individualized iPS approach is that there are no economies of
scale. Each patient needs to have a distinct iPS cell line created
using their unique cells, and each cell line needs to be
individually tested for efficacy and safety before it can be used
for therapy.38 In addition to being expensive (one estimate
places the cost of creating an individual iPS cell line suitable for
therapeutic use at $100,000 or more), this process is also time
consuming and may make it impracticable to use iPS cell lines to
37. It is likely that at least some immunosuppression drugs are necessary in
connection with therapies using embryonic stem cells. This is because embryonic
stem cells are derived from blastocysts created in vitro and not from the patient's
own cells. However, the degree of immunosuppression required, and the ability of
the human body to tolerate stem cells derived from a foreign source, will not be
known until more clinical trials using embryonic stem cells are conducted.
One possible method for resolving the immunosuppression issue is through the
process of therapeutic cloning, also called Somatic Cell Nuclear Transfer ("SCNT").
This process creates a blastocyst by combining an unfertilized egg with a cell
nucleus containing the DNA of the patient. The egg is then given a charge of
electric current to induce cell division and an embryonic stem cell line is then
created through the normal process. The result is to create a stem cell line that
shares the patient's DNA. Therapeutic cloning is perhaps the most controversial
form of stem cell research due to the fear, among some segments of the public, that
the embryos created via this process would not be used for research but would
rather will be implanted in a women's uterus and brought to term (so-called
"reproductive cloning"). Supporters of hESC research typically favor a ban on
reproductive cloning, but resist efforts to ban therapeutic cloning. Under current
guidelines at the National Institutes of Health (NIH), no federal dollars are
available to fund research using stem cell lines derived through therapeutic cloning.
See 10 7 h Congress Stem Cell Research, NAT' INSTS. HEALTH RES. STEM CELL RESEARCH,
http://stemcells.nih.gov/policy/legislation/archive107.htm (last modified Feb. 18,
2009).
38. Paul Knoepfler, Not Ready For Prime Time: The Three Critical Challenges for
IPS Cells, KNOEPFLER LAB STEM CELL BLOG (Oct. 27, 2010, 1:55 PM),
http://www.ipscell.com/home.php?s-not-ready-for-prime-time-the-three-critical-
challenges-for-ips-cells.
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treat fast moving diseases. 39 In contrast, embryonic stem cell
lines can be used to create "batches" of clinically tested and
approved stem cells that would be available "off the shelf" at a
lower per patient cost. The clinical trial begun by the company
Geron in the fall of 2010, to treat spinal cord injuries, uses a
hESC-based drug that was created in this latter fashion.40
Finally, direct re-programming, while promising, possesses
many of the same disadvantages as adult stem cells and iPS
cells. The direct re-programming process is both expensive and
time consuming as compared to the hESC process. Similar to the
case with iPS cell lines, relatively small amounts of replacement
cells are produced by direct re-reprogramming, whereas large
quantities of cells are needed for transplant therapies. Finally,
the long term behavior of cells created via direct re-
programming is unknown. More study is necessary in order to
determine the degree to which this type of cell shares the same
worrisome characteristics as iPS cells, such as the retention of a
"memory" of its prior state or a tendency towards tumor
formation.
Taken in combination, the disadvantages of each particular
type of stem cell research may be less significant than when
viewed in isolation. It is quite possible that any "cure" that
results from stem cell research may result from the use of a
combination of the above approaches being employed to
address different components of a single disease. It is also
possible that therapies derived from adult stem cells may prove
superior to treat certain diseases, while hESC-based therapies
turn out to be the optimal means of treating a different class of
diseases.
The existence of the alternatives of adult stem cells, iPS cells
and direct reprogramming do not render embryonic stem cell
research unnecessary or obsolete. The replacement cells created
by these four different techniques are not identical. At this point
in time, researchers don't know enough about iPS cells or about
39. Id.
40. Id.
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cells created via direct reprogramming to know whether they
are exactly equivalent to the hESC and adult cells that have been
studied for a decade or more. The comparability and
equivalency of these various types of cells will continue to
remain unknown unless parallel experiments are conducted that
compare their longevity and malleability. Therefore, research on
all four types of cells should continue.
Moreover, there are substantial costs associated with the
abandonment of hESC experiments that are already underway.
Important knowledge is being gained every day that will be lost
or delayed for decades if researchers abandon these ongoing
projects. It is striking that the advances that led to both the iPS
and direct reprogramming breakthroughs were made by
researchers applying knowledge obtained from the study of
embryonic stem cell lines. All four types of stem cell research
are related, and all four contribute to a common base of
knowledge that is mutually beneficial.
In summary, there is no scientific rationale that argues in
favor of giving preferential treatment to one type of stem cell
research over another. In light of the science's rapid progress
upon multiple fronts, it is simply premature to declare that any
one form of stem cell research is more likely to lead to therapies
or cures than another, or that any particular type of stem cell
research is unworthy of public funding. Arguments in favor of
directing public funding towards one form of stem cell research
and away from another are premised upon religious or political
agendas.4'
41. See JOHN DANFORTH, FAITH AND POLITICS: HOW THE "MORAL VALUES"
DEBATE DIVIDES AMERICA AND How TO MOVE FORWARD TOGETHER 93 (2006).
Former Senator Danforth writes:
Unlike the issue of abortion, where a fetus in the womb will, with the
passage of time, become a breathing human being, these cells in a petri
dish have no potential other than what scientists can do with them to find
cures for diseases. Calling these blastocysts human life can only be
understood as a statement of religious doctrine, and advancing legislation
to protect them can only be understood as attempting to enforce religion
by resorting to the criminal law.
Id.
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RELIGIOUS AND ETHICAL PERSPECTIVES ON STEM CELL
RESEARCH
THE MORAL STATUS OF THE EMBRYO
Different faith traditions have different beliefs regarding the
moral status of the embryo.42 The Catholic perspective is the
religious point of view that is perhaps the most strongly
opposed to hESC. Official Catholic doctrine holds that life
begins at the moment that the sperm and egg unite, and that the
human embryo is therefore a person entitled to the same rights
and dignity as any other person.43 The destruction of an
embryo, under this view, is the equivalent of the taking of a life.
Catholic doctrine also opposes the creation of an embryo for
purposes other than procreation, and is critical of embryos being
used for research on the grounds that it treats human life as the
mere means to an end.
Protestant opposition to hESC research has come from the
Southern Baptist Convention and from fundamentalist
Protestant denominations. These Christian churches emphasize
a strict interpretation of biblical language, focusing on passages
that suggest that God recognizes the pre-born. In addition, these
denominations emphasize that embryonic stem cell research is
42. Although it is common in public debate to refer to the blastocyst as an
"embryo," the technical meaning of the word "embryo" applies only to a blastocyst
that has attached to the uterus and has subsequently developed a structure called
the "primitive streak" which lays out the body plan of the developing fetus. In the
human body, the developing fetus reaches this stage approximately fourteen days
after fertilization. Prior to this point, it is more accurate to refer to the blastocyst as
a "pre-embryo." See EVE HEROLD, STEM CELL WARS: INSIDE STORIES FROM THE
FRONTLINES 121-22 (2006). However, despite the technical meaning of the word
"embryo," commentators outside of the medical profession typically use the word
"embryo" to refer to the fertilized egg at every stage of its development subsequent
to the union of sperm and egg. The discussion in this section will employ the word
"embryo" as it is commonly used by the public rather than in its more limited
technical meaning.
43. Norman Ford, The Human Embryo as Person in Catholic Teaching, 1 THE
NAT'L CATH. BIOETHICS Q. 155, 159-60 (2001).
2632011]
MARQUETTE ELDER'S ADVISOR
incompatible with the Christian mandate to protect the most
vulnerable members of society, a group which they believe
includes the embryo. The National Association of Evangelicals
has issued the following policy statement explaining its
opposition to embryonic stem cell research:
All humans, male and female, are made in the image of
God (Genesis 1:27) and, therefore, have intrinsic dignity
that should be respected and honored. Indeed, the
breath of life in all human beings is a gift from God
(Genesis 2:7) and thus inherently holy. The NAE has
pledged to protect the sanctity of human life and to
safeguard its nature. Thus, the NAE opposes all
human cloning, including cloning human embryos for
laboratory experimentation, as well as discrimination
based on genetic identities. The NAE welcomes and
supports medical research that uses stem cells from
adult donors and other ethical avenues of research."
In contrast, many mainline Protestant denominations have
issued statements in support of embryonic stem cell research.
One of the basic tenets of the Protestant Reformation was the
embrace of the family as the basic unit of society, and this has
found expression in a more accepting attitude towards non-
procreative sexual relations between husband and wife than
under Roman Catholicism. 45  In the United States, many
mainline Protestant denominations have accepted contraception
and abortion as questions of child-bearing that are appropriately
left to the individual conscience of the woman.46 These Christian
denominations focus on implantation in the womb as a more
significant event than fertilization in the formation of
personhood; the development of the fetus is seen as a process
whereby personhood is attained gradually. Protestant
denominations that support embryonic stem cell research
44. Respecting Human Dignity in Biotechnology, NAT'L ASS'N OF EVANGELICALS
(2009), http://www.nae.net/fthn/respecting-human-dignity-in-biotechnology.
45. Gloria H. Albrecht, Contraception and Abortion Within Protestant Christianity,
in SACRED RIGHTS: THE CASE FOR CONTRACEPTION AND ABORTION IN WORLD
RELIGIONS 79, 89-91 (Daniel C. Maguire ed., 2003).
46. Id. at 94-96.
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include the Episcopal Church,47 the Presbyterian Church
(USA),48 the United Church of Christ,49 United Methodist
Church,s0 and the Unitarian Universalist Association of
Congregations.51
Jewish scholars also have been supportive of embryonic
stem cell research. The traditions of Judaism recognize that
personhood begins with the child's birth, and not before.
Therefore, Judaism does not accord the embryo a moral standing
outside of the womb independent of the mother.5 2 All of the
major Jewish denominations support medical research using
hESC: Reform, 53  Conservative,5 4  Orthodox,55  and the
Reconstructionist Rabbinical Association. 56 In addition, Islamic
scholars have been supportive of embryonic stem cell research
when it is conducted for purposes of curing disease.5 7
47. Episcopal Church, Resolution 2003-A014: Support Human Embryonic Stem
Cell Research, THE ARCHIVES OF THE EPISCOPAL CHURCH (2003),
http://www.episcopalarchives.org/cgi-bin/acts/acts-resolution.pl?resolution=2003-
A014.
48. Presbyterians Vote in Favor of Fetal, Embryonic, and Stem Cell Research,
SCIENCE BLOG (2001), www.scienceblog.com/community/older/2001
/D/200114185.html.
49. Twenty-Third Synod of the United Church of Christ, Support for Federally
Funded Research of Embryonic Stem Cells, UNITED CHURCH OF CHRIST (2001),
http://www.ucc.org/synod/resolutions/SUPPORT-FOR-FEDERALLY-FUNDED-
RESEARCH-ON-EMBRYONIC-STEM-CELLS.pdf.
50. Ethics of Embryonic Stem Cell Research, THE UNITED METHODIST CHURCH
(2004), http://archives.umc.org/interior.asp?ptid=4&mid-6560.
51. Pass the Stem Cell Research Enhancement Act, UNITARIAN UNIVERSALIST
ASS'N OF CONGREGATIONS, http://www.uua.org/socialjustice/socialjustice/
statements/8064.shtml (last updated June 3, 2010).
52. See Yoel Jakobovits, Judaism and Stem Cell Research, TORAH.ORG (2002),
http://www.torah.org/features/secondlook/stemcell.html.
53. Urge the Senate to Support Stem Cell Research and Save Lives, RELIGIOUS
ACTION CTR. OF REFORM JUDAISM, http://rac.org/advocacy/issues/stemcell/#rjm (last
updated July 26, 2005).
54. Stem Cell Research and Education, THE UNITED SYNAGOGUE OF
CONSERVATIVE JUDAISM (2003), http://www.uscj.org/StemCellResearch
_a6675.html.
55. Union of Orthodox Jewish Congregations Welcomes U.S. House Passage of Stem
Cell Research Enhancement Act, ORTHODOX UNION INST. FOR PUB. AFFAIRS (May 25,
2005), http://www.ou.org/public/statements/2005/n11.htm.
56. Resolution on Educational and Political Support of Stem Cell Research,
RECONSTRUCTIONIST RABBINICAL ASS'N (March 15, 2005),
http://www.therra.org/members/conv2005/Res-StemCell-2005.pdf.
57. Muzammil Siddiqi, An Islamic Perspective on Stem Cells Research, ISLAM101,
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Other faith traditions have taken no official position either
in favor of or against embryonic stem cell research. Religious
faiths that have not expressed an official position include the
Church of Jesus Christ of Latter Day Saints," Hinduism", and
the American Baptist Churches.6 0
THE CALL TO HEAL THE SICK
In addition to the moral status of the embryo, there is a
separate faith tradition that is implicated by stem cell research.
Many religious denominations teach that society has an
affirmative obligation to heal the sick and to comfort those
afflicted with disease. For example, the Jewish faith includes a
calling to pursue medical research as an affirmative duty, one
that is often cited by Jewish supporters of stem cell research. In
addition, the more "liberal" Protestant denominations
traditionally have embraced the benefits of scientific progress,
and have accepted human reason and new discoveries as a force
for good in the world. 61 Persons from these Christian
denominations who express support for embryonic stem cell
research often point to Jesus' miracles in healing the sick, and
call on mankind to follow Jesus' example.
Bioethicist Laurie Zoloth has summarized the challenge
presented by these alternative moral perspectives on medical
research:
I argue that the free inquiry of research science can be
understood as a sort of free speech. It is protected by
the larger social polity, and it has to be responsive to
http://www.islaml0l.com/science/stemCells.htm (last visited March 14, 2011).
58. Embryonic Stem-Cell Research, THE CHURCH OF JESUS CHRIST OF LATTER-DAY
SAINTS, http://beta-newsroom.lds.org/official-statement/embryonic-stem-
cell-research (last visited March 14, 2011).
59. Pankaj Mishra, How India Reconciles Hindu Values and Biotech, N.Y. TIMES,
Aug. 21, 2005, at WK4.
60. See generally Religious Groups' Official Positions on Stem Cell Research, THE
PEw FORUM ON RELIGION & PUB. LIFE (July 17, 2008), http://pewforum.org
/Science-and-Bioethics/Religious-Groups-Official-Positions-on-Stem-Cell-
Research.aspx.
61. See Albrecht, supra note 45, at 84.
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the larger civic discourse, and to the meaning of the
moral gesture of medicine. If medicine's future lies in
genetics knowledge, how will such terrain shape our
view of the self? If medicine's future lies in
transgression of boundaries understood as natural,
how will we reconstruct a robust sense of morality and
of a connection to the narrative past?
We live in the world as we find it, but medicine is, in
a sense, about the world as we imagine it could be. The
task of the next century in medicine will be a complex
and difficult freedom, for with emerging,
transformative powers will come serious and vexing
challenges. Creating a duty-based response in research
as well as in medicine will be needed if the calling at
the heart of medicine continues to guide the work of
the physician ....
Different faith traditions-Buddhist, Hindu, Sikh,
Muslim, and Jewish as well as Christian sensibilities-
will need to be considered now, and in most of these,
the duty to heal the sick and the need for free scientific
inquiry will be the primary considerations in this work.
For many whose religion now prohibits any use of the
early embryo, no matter how it is created, much of this
research will be impermissible. But others will argue
that this opens the door to a critical research direction.
Each member of the clergy and each lawmaker must
think: how do we balance the many competing moral
appeals? 62
Much of the controversy surrounding stem cell research can
be traced to the existence of distinctive moral perspectives
among persons of different faith traditions.
GUIDELINES FOR ETHICAL RESEARCH
Because stem cell research uses human tissue, it raises many
of the same ethical issues involved in any other type of medical
research involving humans. Most, if not all, research institutions
have adopted guidelines to ensure that embryonic stem cell
research progresses in an ethical manner. For example, before
62. Laurie Zoloth, Living Under the Fallen Sky: Science and Religion Meet
Naturally, if Uneasily, in Healing, 36 HARV. DIVINITY BULL. (Spring 2008), available at
http://www.hds.harvard.edu/news/bulletin mag/articles/36-2/zoloth.html.
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engaging in embryonic stem cell research, scientists at the
University of Wisconsin entered into contracts with the donors
of blastocysts created for in vitro fertilization purposes, in order
to establish a system of informed consent. 63 These contracts also
provided that only blastocysts that had previously been frozen
would be made available for research and that no financial
compensation would be paid to the donors.6 4 In addition,
researchers at the University of Wisconsin sought and received
approval from the university's twenty-four person institutional
review board, which concluded that the research could be
conducted ethically after reviewing the work of national review
boards in both the United Kingdom and Canada, as well as the
report of the NIH's Human Embryo Research Panel.65
Since 2005, the National Academies of Sciences has
maintained guidelines that call on all research institutions
conducting embryonic stem cell research to establish a
committee charged with Embryonic Stem Cell Research
Oversight (ESCRO).66 The ESCRO Committee would be charged
with the oversight of all issues related to the derivation and use
of embryonic stem cells. The current guidelines also call for
institutions to document the provenance of stem cell lines
utilized for research in order to verify that they were obtained
with informed consent, 67 and to prohibit any payment to the
donors of blastocysts beyond direct expenses.68 In addition, the
guidelines state that no embryonic stem cell research should be
conducted that involves the use of blastocysts beyond the
63. See Sanjay Jain & Gerard George, Technology Transfer Offices as Institutional
Entrepreneurs: The Case of Wisconsin Alumni Research Foundation and Human
Embryonic Stem Cells, 16 INDUS. & CORP. CHANGE 535, 546 (2007).
64. Id.
65. Id. at 545.
66. HUMAN EMBRYONIC STEM CELL RESEARCH ADVISORY COMMITTEE, NAT'L
RESEARCH COUNCIL AND INST. OF MED. OF THE NAT'L ACADS., 2008 AMENDMENTS
TO THE NATIONAL ACADEMIES' GUIDELINES FOR HUMAN EMBRYONIC CELL
RESEARCH, Appendix A Guideline 2.0 (2008), available at
http://books.nap.edu/openbook.php?record-id=12260&page=21#p20015de59970021
001.
67. Id. at Guideline 3.6.
68. Id. at Guideline 3.4.
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fourteenth day of development, or after the formation of the
primitive streak, whichever occurs first.69
In July 2009, the NIH adopted new guidelines that state
which embryonic stem cell lines currently are eligible to receive
federal funding. The NIH guidelines largely parallel the
National Academies of Sciences recommendations on the issues
of informed consent and the prohibition of compensation.
However, under the current NIH guidelines, federal funding is
limited to hESC lines derived from blastocysts created for
purposes of in vitro fertilization.70
THE CURRENT FUNDING LANDSCAPE
Depending upon one's perspective, the current funding
landscape for stem cell research in the United States can either
be applauded as an experiment in federalism or else decried as
having caused the balkanization of medical research. Currently,
funding for stem cell research is provided in various forms and
in various amounts by the federal government (through the
NIH), by several state governments, and by private actors such
as philanthropic foundations and investors in biomedical
companies. This funding landscape has developed over time,
not due to any plan or conscious design, but rather as a result of
the fact that "[f]or the past thirty years the political branches
have been locked in a stalemate on the issue."71
A BRIEF HISTORY OF FEDERAL FUNDING
A brief summary of the history of federal funding of
embryonic stem cell research is helpful at this point. The 1993
National Institutes of Health Revitalization Act removed legal
69. Id. at Guideline 4.5.
70. Raynard S. Kingston, 2009 Guidelines on Human Stem Cell Research, THE
NAT'L INSTS. OF HEALTH, http://stemcells.nih.gov/policy/2009guidelines.htm
(last visited April 4, 2011). For an analysis of the current NIH guidelines, see Wise
Young, Analysis of 2009 NIH Human Stem Cell Research Policy, WISE
YOUNG@CARECURE (July 9, 2009), http://wiseyoung.wordpress.com/2009/07/15/287/.
71. Snead, supra note 1, at 1545.
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impediments that had previously prevented the NIH from
awarding federal funds to support research using human
embryos. 72 In September 1994, the NIH Human Embryo Panel,
responding to a charge from President Clinton, issued a report
recommending that some areas of human pre-embryo research
receive federal funding, and making no distinction between
excess blastocysts created during the in vitro fertilization process
and blastocysts created expressly for research.73 President
Clinton, however, directed the NIH not to allocate any resources
that supported the creation of blastocysts expressly for research
purposes.74
However, before any regulations were adopted authorizing
the federal funding of stem cell research, Congress passed the
Dickey-Wicker Amendment. Attached as a rider to an omnibus
appropriations bill, and signed into law by President Clinton,
the Dickey-Wicker Amendment prohibits the use of federal
funds for the creation of a "human embryo" for research
purposes or for research "in which a human embryo or
embryos" are destroyed.75 The Dickey-Wicker Amendment has
been reauthorized every year subsequent and is currently in
force.
In 1998, the Department of Health and Human Services
issued an interpretation of the Dickey-Wicker Amendment
concluding that the law did not prohibit the federal funding of
research using stem cell lines that were derived from blastocysts
that had been previously destroyed using private funding.76
However, the Clinton Administration came to an end before any
federal funds were allocated to support embryonic stem cell
research under this interpretation. President Bush agreed with
the Clinton Administration's interpretation of the Dickey-Wicker
Amendment, however, and under his administration the NIH
72. Id.
73. Id. at 1546.
74. Id.
75. Id.
76. Id. at 1546-47.
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awarded federal funds to support embryonic stem cell research
for the first time.77 However, President Bush directed that the
only embryonic stem cell lines eligible to receive federal funding
would be those that were already in existence on August 9, 2001,
the date on which his policy was announced.78 The reason for
this limitation was to ensure that federal funding did not create
incentives for the "further destruction of human embryos." 7 9 As
the months passed after President Bush announced his policy, it
became apparent that only twenty-one embryonic stem cell lines
were both suitable for research purposes and eligible to receive
federal funding.s0
On two separate occasions, Congress passed legislation that
would have broadened federal funding of embryonic stem cell
research to allow research using any blastocyst that was created
during the in vitro fertilization process and that had been
donated for research purposes with informed consent, but on
both occasions Congress failed to override President Bush's
veto.81 The Bush Administration guidelines remained in place
from 2001 until March 9, 2009 when they were rescinded by
President Obama.82
In July of 2009, the NIH issued new guidelines that
permitted the use of federal funds for embryonic stem cell
research so long as the blastocyst had been originally created for
reproductive purposes and were donated with informed
consent.83 The new NIH guidelines do not permit federal funds
to be used for research that involves therapeutic cloning. In
77. Id. at 1550.
78. Id.
79. President George W. Bush, Announcement to Allow Federal Funding for
Research on Existing Stem Cell Lines (Aug. 9, 2001) (transcript available at
http://www.speakout.com/activism/apstories/10048-1.html).
80. Snead, supra note 1, at 1550.
81. Id. at 1551.
82. See President Barack Obama, Remarks Prepared for Delivery Signing of
Stem Cell Executive Order and Scientific Integrity Presidential Memorandum
(March 9, 2009) (transcript available at http://www.whitehouse.gov
/thepressoffice/Remarks-of-the-President-As-Prepared-for-Delivery-Signing-of-
Stem-Cell-Executive-Order-and-Scientific-Integrity-Presidential-Memorandum/).
83. Snead, supra note 1, at 1552-53.
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promulgating the new NIH guidelines, the Obama
Administration joined the Clinton and Bush Administrations in
interpreting the Dickey-Wicker Amendment to allow such
funding.
ANALYSIS OF CURRENT FEDERAL AND STATE FUNDING
ALLOCATION
Currently, the federal funding of embryonic stem cell
research lags well behind federal funding for alternative
methods of stem cell research. The Fiscal Year 2010 budget for
the NIH allocated $126 million to hESC research, and it is
estimated that $125 million will be allocated to embryonic stem
cell research by the end of Fiscal Year 2011.84 The current
estimate of hESC funding in the Fiscal Year 2012 NIH budget is
approximately $128 million.85 In contrast, the Fiscal Year 2010
budget for the NIH allocated $341 million for non-embryonic
forms of human stem cell research, and it is estimated that the
Fiscal Year 2011 NIH budget will fund non-embryonic research
in an equal amount.86 In addition, funding of non-human
(animal) stem cell research in Fiscal Year 2010 equaled $745
million, and it is expected that in Fiscal Year 2011 the NIH will
fund research using non-human (animal) stem cells in the
amount of $744 million.87 In summary, between 2007 and 2010
the NIH budget has never allocated more than 11% of the annual
research budget for stem cell research to hESC research. This
trend is set to continue in 2011 when hESC research will
constitute a mere $125 million out of a total budget of $1.098
billion.88
Federal funding of embryonic stem cell research is also
being outpaced by state funding. Between December 2005 and
84. Nat'1 Insts. Health Research Portfolio Online Reporting Tools, Estimates of
Funding for Various Research, Condition, and Disease Categories, U.S. DEP'T OF HEALTH
& HUMAN SERVS. (Feb. 14, 2011), http://report.nih.gov/rcdc/categories/.
85. Id.
86. Id.
87. Id.
88. Id.
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the end of 2009, six states89 awarded a total of $1.25 billion in
grants to support all types of stem cell research. 90 Within the
individual states, funding priorities vary among adult,
embryonic, or iPS research. A full 75% of California's grants
went to support hESC research, as did 97% of Connecticut's
grants.9' In contrast, New York only awarded 21% of its grants
to support hESC research, with the bulk of its research dollars
awarded for the study of iPS cells.9 2 Maryland and Illinois have
funded a varied mix of adult and hESC research.93 Among
them, these six states governments - and not the federal
government - have provided the majority of research dollars
spent on hESC research.94
While some private foundations, such as the Juvenile
Diabetes Research Foundation, are known to be significant
funders of embryonic stem cell research, there is no national
data that reveals the total amount of private dollars spent on
stem cell research or that identifies the allocation of those dollars
among hESC, adult or iPS cells. Philanthropic funding can
shrink during economic downturns, and it is unknown what
impact the recent recession has had on research funding by
private foundations. Some experts predict that for-profit
corporate funding will become an increasingly significant
contributor to the funding of stem cell research, due to the
uncertainties of philanthropic and government funding.95
However, close ties between medical researchers and for-profit
biotech companies raise their own distinct concerns. Some fear
that an increased reliance on corporate funding means that
89. These states are California, Connecticut, Illinois, Maryland, New Jersey,
and New York. Ruchir N. Karmali et al., Tracking and Assessing the Rise of State-
Funded Stem Cell Research, 28 NATURE BIOTECHNOLOGY 1246, 1247 tbl.1 (Dec. 2010).
90. Id. at 1246.
91. Id. at 1247 tbl.1.
92. Id.
93. Id.
94. Id. at 1247 (noting that state funding of hESC research on a cumulative
basis from 2005 through 2009 exceeded NIH funding for hESC research during the
same period).
95. See Jessica Reaves, Stem Cell Research Skirts Hurdles, but Raises Ethics Issues,
Too, N.Y. TIMES, Oct. 22, 2010, at A23.
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financial results will dictate the course of research, rather than
purely scientific considerations. 96
It appears unlikely that the traditional paradigm of the
National Institutes of Health serving as the single funding
mechanism for basic medical research will ever be attained in
the case of stem cell research. Despite the efforts of the Obama
Administration to expand the types of stem cell lines that are
eligible to receive federal funding, future congressional
restrictions and future legal challenges to administrative
rulemaking will almost certainly continue, and any hope of an
uninterrupted stream of NIH funding is slim. In such an
environment, it is doubtful that states will abandon their parallel
funding schemes, while other alternatives to federal funding,
such as state-private funding partnerships, will be explored.
While it is unfeasible to dismantle state funding schemes for
stem cell research at this time, it is nonetheless worth examining
the reasons why a unified federal funding scheme administered
through the NIH is the preferred mechanism for funding
medical research. First of all, unified funding through the NIH
promotes an allocation of resources that directs research dollars
to the most meritorious projects. This is because channeling
grant requests through a single funder allows that funder to use
uniform application guidelines and a rigorous peer review
process in order to select the most promising projects. It is
inefficient for individual states to replicate this administrative
infrastructure, and, by splitting the application pool among
multiple funding sources, it is also possible that worthy
applications will fall through the cracks.
Another advantage of federal funding of medical research is
that it promotes collaboration among researchers nationwide.
The NIH can impose uniform guidelines and ethical standards
concerning the derivation, donation, and cultivation of stem cell
lines. By creating a set of research data where all projects
comply with the same standards, researchers can more easily
96. Id.
[Vol. 12274
FUNDING STEM CELL RESEARCH
share their data and compare results. In addition, collaboration
is more easily fostered by a single nationwide funder, both
because the NIH can give preference to joint projects and
because state boundaries need not constrain where the funds are
spent.
The expected high demand among the public to participate
in clinical trials for stem cell therapies provides another reason
to prefer channeling research funding through the NIH. State
funded clinical trials are likely give priority to state residents,
given that state tax dollars were used to fund the underlying
research. However, patients outside of the funding state might
be superior candidates to participate in a clinical trial. A federal
funding scheme ensures that only medical criteria are used to
determine access to clinical trials.
In addition, the federal government is in the best position to
ensure transparency, so that the public is fully informed about
what researchers are doing. By accepting federal dollars,
research institutions agree to comply with the NIH's ethical
guidelines and to report on their activities. In contrast, state
funded research operates outside of any federal oversight, and,
while California researchers operate under extensive state
guidelines, other states employ varying degrees of supervision
over the use of state dollars.9 7 Meanwhile, privately funded
research occurs without any government oversight at all. The
use of federal funding serves an important function both as a
means of imposing ethical limits on the research and also in
ensuring a level of public oversight. Without federal funding, a
greater percentage of this research will occur outside of the
public eye.
Finally, federal funding of research also helps to promote
industry standards and practices that eventually will be adopted
by for profit entities. An absence of federal funding is the
97. See generally Lori P. Knowles, State-Sponsored Human Stem Cell Research:
Regulatory Approaches and Standard Setting, in STATES AND STEM CELLS: A SYMPOSIUM
ON THE POLICY AND ECONOMIC IMPLICATIONS OF STATE-FUNDED STEM CELL
RESEARCH 75-111 (Aaron D. Levine ed., 2006).
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equivalent of an absence of federal rules. Already, overseas
stem cell clinics are marketing their services to residents of the
United States. The growth of "stem cell tourism" is of great
concern, especially given the wild claims and unproven
therapies that are being touted by many foreign companies. At
some point in the future, companies will team with scientists in
order to offer stem cell based therapies to the public
domestically. Without federal research grants and standards,
practices in the field will be driven by market forces rather than
government created guidelines. The infertility industry is an
example of a medical specialty that has grown largely
independent of federal funding and oversight throughout its
history, leading bioethicist Arthur Caplan to refer to in vitro
fertilization clinics as "the wild, wild west of medicine." 8
While the federal funding of medical research offers several
advantages, a scheme that relies on multiple state funders
presents several disadvantages. First, state funding sources
typically impose legal restrictions that limit the use of state
funds to research that is conducted within the state's borders.
For example, money granted to researchers by the California
Institute of Regenerative Medicine must be spent in California.99
These restrictions make it difficult for researchers in different
states to collaborate with each other.
Second, various forms of regulatory inconsistency are
created where there are multiple funders of basic research, even
beyond restrictions on the use of research dollars. 00 Perhaps the
98. Tamara Audi & Arlene Chang, Assembling the Global Baby, WALL ST. J., Dec.
20, 2010, http://online.wsj.com/article/SB10001424052748703493504576007774
155273928.html
99. CALIFORNIA INST. FOR REGIONAL MEDICINE, CIRM GRANTS
ADMINISTRATION POLICY FOR ACADEMIC AND NON-PROFIT INSTITUTIONS 13 (April
28, 2009), http://www.cirm.ca.gov/files/Regulations/NPGAP_042809a.pdf ("CIRM-
funded research must be conducted in California."). Private funders of stem cell
research, such as the Juvenile Diabetes Research Foundation, also place restrictions
on the use of their funds.
100. See generally Geoffrey Lomax & Susan Stayn, Similarities and Differences
Among State Stem Cell Policies: Opportunities for Policynakers, Patients, and Researchers,
7 MED. RES. L. & POL'Y REP. 695 (2008), reprinted in BUREAU OF NAT'L AFFAIRS INC., 4
(2008).
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most vexing inconsistencies involve intellectual property rights.
For example, when universities and research institutions license
patented technology that they have developed using private
funds, these institutions will often assert the right to exercise
control over any discoveries that result from the use of the
patented technology. 10' In patent law, this is called a "reach
through,"102 and critics assert that the aggressive assertion of
patent rights on basic scientific methods can chill future research
that seeks to build on the prior discoveries.
The NIH has used its influence as a funder of embryonic
stem cell research to address concerns over "reach through"
patent rights. The patent rights to the methods used to isolate
human embryonic stem cell lines are owned by the Wisconsin
Alumni Research Foundation (WARF). Many scientists objected
to the license agreements by which WARF originally made
embryonic stem cell lines available to researchers around the
country, on the grounds that the agreements contained a
provision retaining "reach through" rights for WARF covering
any commercial applications developed by licensees. The NIH
and WARF were able to negotiate an agreement that clarified the
extent and timing of any "reach through" rights in cases where
stem cell research is funded by the federal government. The
existence of this agreement largely satisfied the concerns of
researchers.103 However, state funding regimes create additional
101. U.S. GOV'T ACCOUNTABILITY OFFICE, GAO-03-536, TECHNOLOGY TRANSFER:
AGENCIES' RIGHTS TO FEDERALLY SPONSORED BIOMEDICAL INVENTIONS 3, 4 (2003),
available at http://www.gao.gov/new.items/d03536.pdf.
102. See generally, Stephen G. Kunin et al., Reach-Through Claims in the Age of
Biotechnology, 51 AM. U. L. REV. 609, 618 (2002).
103. In 2001, WARF negotiated a Memorandum of Understanding with the
NIH that permits academic researchers to have broad access to hESC for
-upstream" research while preserving WARF's interest in "downstream"
commercial applications. See Rebecca S. Eisenberg & Arti K. Rai, Proprietary
Considerations, 1 HANDBOOK OF STEM CELLS 793, 793 (2004); see also Jain, supra note
63, at 548.
In general, the NIH utilizes a Resource Sharing Plan that gives researchers an
incentive to waive certain intellectual property rights in exchange for receiving
federal funding. See Office of Extramural Research, NIH Data Sharing Policy and
Implementation Guidance, U.S. DEP'T OF HEALTH & HUMAN SERVS.,
http://grants2.nih.gov/grants/policy/data-sharing/data-sharing-guidance.htm (last
updated March 5, 2003).
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and perhaps conflicting rules that govern the exercise of "reach
through" rights in the context of research funded by the states
rather than by the federal government. 104 It is unclear whether
the existence of inconsistent state rules regarding intellectual
property rights has had a detrimental effect on the progress of
embryonic stem cell research to date, but it is indisputable that
the legal rights attached to new discoveries are more likely to
promote innovation when they are uniform and predictable
rather than conflicting and uncertain.105
There are also indications that the balkanized funding
landscape itself has influenced the types of stem cell research
that have received government funding. First of all, evidence
shows that a substantial amount of hESC research currently
being funded by the states would have qualified for federal
funding even under the Bush administration's 2001 NIH
guidelines. 106 This fact suggests that there is a greater demand
for federal dollars to support embryonic stem cell research than
the NIH has been able to satisfy. It also suggests that the total
amount of federal funding is insufficient even to support
research using the original twenty-one hESC lines, much less to
support research on all four types of stem cells.107
Moreover, the funding data shows that the majority of those
receiving state grants have not previously received NIH funding
104. Owen Hughes, Pfizer, Remarks at the World Stem Cell Summit 2008 (Sept.
23, 2008) (transcript available at http://worldstemcell08.blogspot.com
/2008_09_01_archive.html (speaking at the 2008 World Stem Cell Summit in
Madison, Wisconsin, he stated:
Nobody quite knows yet how it will play out . and it will get more
complicated if the NIH decides to enter the funding arena. The trigger
points for the reach through events will be different for feds and states,
and we don't clearly know what they are.).
105. See generally Roger G. Noll, Designing an Effective Program of State-Sponsored
Human Enbryonic Stemn Cell Research, 21 BERKELEY TECH. L. J. 1143, 1149-53 (2006).
106. See Karmali, supra note 89, at 1247.
107. On average, only twenty percent of applications for grants to support
biomedical research receive NIH funding. Nat'l Insts. of Health Research Portfolio
Online Reporting Tools, Research Project Success Rates by NIH Institute for 2010, U.S.
DEP'T OF HEALTH & HUMAN SERVS. http://report.nih.gov/award/success/Success
ByIC.cfm (Last updated Dec. 14, 2010).
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for stem cell-related research.108 It appears that the existence of
state funding schemes has drawn new researchers into the
field.109 However, it is not clear that expanding the universe of
grant recipients will necessarily lead to better research results,
especially when scientists with more experience working with
stem cells are struggling to obtain funding. Those who receive
state funds may not always have submitted the best research
proposals. Rather, a particular state may be funding mediocre
proposals submitted by inexperienced researchers simply
because those are the best applications received from a resident
of that state. At the same time, experienced researchers are
losing out on funding opportunities as a result of inadequate
federal funding combined with simply being a resident in the
wrong state. This geographic disparity in funding creates a
strong incentive for scientists to relocate away from states that
lack a funding mechanism and to move to states where a stable
source of research funding is available.'
LITIGATION AS A STRATEGY TO DISRUPT GOVERNMENT
FUNDING
Research projects involving embryonic stem cell lines require an
uninterrupted stream of funding in order to succeed. While the
uncertain and changeable nature of governmental funding
policies can impact this stream, funding is also vulnerable to
disruption by non-governmental sources. In two high profile
instances, groups with religious objections to embryonic stem
cell research have used litigation in an attempt to disrupt the
108. See Karmali, supra note 89, at 1247.
109. Id.
110. See Aaron D. Levine, Research Policy and the Mobility of U.S. Stem Cell
Scientists, 24 NATURE BIOTECHNOLOGY 865, 866 (2006) (concluding that stem cell
scientists are more likely to receive job offers to move to new positions in states and
foreign countries than are scientists in other biomedical fields, and stating that this
data "lend[s] credence to the claim that federal funding restrictions are negatively
affecting the field's development in the United States"); see generally Aaron D.
Levine, Policy Considerations for States Supporting Stem Cell Research: Evidence from a
Survey of Stem Cell Scientists, 68 PUB. ADMIN. REV. 681 (2008).
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financing of research."
THE CALIFORNIA EXPERIENCE
In November 2004, the voters of California approved a
state-wide referendum to amend the state Constitution known
as Proposition 71. The terms of Proposition 71 authorized the
state to issue $3 billion in general obligation bonds in order to
support stem cell research. 112  It also created the California
Institute of Regenerative Medicine (CIRM) to serve as the vehicle
for the award and supervision of research grants using this
fund.113
However, almost immediately after Proposition 71 was
passed, a series of lawsuits were filed in California state courts
seeking to prevent the state from issuing the bonds. These
lawsuits challenged the impartiality of the governing board of
CIRM, alleged that the lack of state oversight over the operations
of CIRM violated the California Constitution, and charged that
the language of Proposition 71 violated the single subject
requirement for state-wide initiatives. 114  Funding for these
lawsuits was provided by pro-life organizations seeking to
overturn Proposition 71 or to delay its implementation for as
long as possible.13 The ongoing litigation prevented California
from issuing the bonds authorized by Proposition 71 for over
two years, and bond sales did not occur until May 2007.116 In
order to award research grants in the interim, CIRM was forced
to borrow $45 million and obtain $150 million in bridge
financing from the state treasury."7 The California Court of
111. See Noll, supra note 105, at 1156-57.
112. David Gollaher, The California Experiment, J. OF LIFE SCIENCES, Sept. 2007, at
48, 50.
113. Id.
114. See Joel W. Adelson & Joanna K. Weinberg, The California Stem Cell
Initiative: Persuasion, Politics, and Public Science, 100 AM. J. PUB. HEALTH 446, 448
(2010).
115. Id.; see also Gollaher, supra note 112, at 51.
116. See Gollaher, supra note 112, at 51.
117. Id.
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Appeals ruled in CIRM's favor in February 2007.118
SHERLEY V. SEBELIUS
In August 2009, a lawsuit styled Sherley v. Sebelius"19 was
filed in federal district court challenging the NIH guidelines
issued one month previously by the Obama administration.
Among the named plaintiffs were two faith-based organizations.
The plaintiffs argued that the July 2009 NIH guidelines, which
expanded federal funding of hESC research beyond the twenty-
one lines approved under the prior guidelines, violated the
Dickey-Wicker Amendment. Judge Royce Lamberth granted the
preliminary injunction sought by the plaintiffs, preventing the
NIH from expending any federal funds until the completion of a
trial on the merits.
Judge Lamberth concluded that the language of the Dickey-
Wicker Amendment unambiguously prohibited the use of
federal funds for research purposes if a blastocyst had been
destroyed at any stage leading up to the federally funded
portion of the research:
The language of the statute does not support
defendants' alternative definition of research as 'a piece
of research.' Indeed, the Dickey-Wicker Amendment
does not contain any language to support such a
limited definition of research. Rather, the language of
the statute reflects the unambiguous intent of Congress
to enact a broad prohibition of funding research in
which a human embryo is destroyed. This prohibition
encompasses all 'research in which' an embryo is
destroyed, not just the 'piece of research' in which the
embryo is destroyed. Had Congress intended to limit
the Dickey-Wicker to only those discrete acts that result
in the destruction of an embryo, like the derivation of
ESCs, or to research on the embryo itself, Congress
118. Cal. Family Bioethics Council v. Cal. Inst. for Regenerative Med., 55 Cal.
Rptr. 3d 272, 312 (Cal. Ct. App. 2007).
119. Shirley v. Sebelius, 704 F. Supp.2d 63, 66 (D.D.C. 2010), vacated by No. 10-
5287, 2011 U.S. App. LEXIS 8686 (D.C. Cir. April 29, 2011).
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could have written the statute that way.120
Judge Lamberth also ruled that that the destruction of
human embryos necessarily occurs when embryonic stem cell
lines are created, thereby triggering the prohibition of the
Dickey-Wicker Amendment:
ESC research is clearly research in which an embryo is
destroyed. To conduct ESC research, ESCs must be
derived from an embryo. The process of deriving ESCs
from an embryo results in the destruction of the
embryo. Thus, ESC research necessarily depends upon
the destruction of a human embryo. 121
Therefore, Judge Lamberth granted the motion for a preliminary
injunction.
Judge Lamberth's ruling can be criticized on several fronts.
First of all, his interpretation of the "unambiguous" language of
the Dickey-Wicker Amendment is contrary to the interpretation
adopted by three separate presidential administrations. This
suggests that the contrary interpretation is at least a permissible
reading of the statutory language and that therefore the federal
courts should defer to the agency interpretation. Second, under
Judge Lamberth's interpretation of the Dickey-Wicker
Amendment, even the Bush administration's 2001 funding
guidelines are unlawful. At no time during the Bush
administration did Congress express such understanding of the
law. Finally, by granting a preliminary injunction, Judge
Lamberth necessarily found that the plaintiffs would suffer
irreparable harm if the NIH guidelines were not immediately
enjoined. 2 2 However, as discussed above, there is absolutely no
evidence that the availability of federal funds for embryonic
stem cell research has limited or detracted from the availability
of funds for research using adult stem cells or iPS cells. The
federal government currently funds far more research using
120. Shirley, 704 F. Supp.2d at 70-71.
121. Id. at 71.
122. Id. at 72 (Judge Lamberth held as follows: "The guidelines, by allowing
federal funding of ESC research, increases [sic] competition for NIH's limited
resources. This increased competition for limited funds is an actual, imminent
injury.").
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adult stem cells than embryonic stem cells, and to date the
primary financial support for embryonic stem cell research has
come from state governments.
In other words, the plaintiffs did not demonstrate a
likelihood of success on the merits of their claim, nor could they
show that they were likely to suffer irreparable harm in the
absence of a preliminary injunction halting the future funding of
embryonic stem cell research. The United States Court of
Appeals for the District of Columbia Circuit held as much on
April 29, 2011, when it vacated Judge Lamberth's order granting
the preliminary injunction.123 The litigation remains ongoing as
this article goes to press.
The decision of the Court of Appeals allows the National
Institutes of Health to continue funding embryonic stem cell
research for the time being. However, while the Circuit Court
expressed skepticism over the plaintiffs' interpretation of the
Dickey-Wicker Amendment, it is still possible that Judge
Lamberth will rule for the plaintiffs on the merits of the case.
Future appeals are likely in either event, perhaps all the way to
the United States Supreme Court. The uncertainty generated by
legal challenges to state and federal funding of embryonic stem
research has had a measurable negative impact on the
development of stem cell science.124
THE NEED FOR NEUTRAL PRINCIPLES TO GUIDE MEDICAL
RESEARCH
As the foregoing discussion illustrates, the rapid progress of
scientific knowledge concerning human stem cells, as well as
religious and political considerations, have worked in
combination to influence the funding landscape for stem cell
research. The result, whether intended or not, has been to turn
123. Sherley v. Sebelius, No. 10-5287, 2011 U.S. App. LEXIS 8686, at *30 (D.C.
Cir. April 29, 2011).
124. See generally Aaron D. Levine, Policy Uncertainty and the Conduct of Stem Cell
Research, 8 CELL STEM CELL 132 (2011).
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the method of funding medical research into a force that
impedes progress. The seeds were sown when the Bush
administration decided in 2001 to limit federal funding to
twenty-one pre-existing hESC lines, thereby creating a de facto
incentive for scientists to develop an over reliance on a limited
subset of hESC lines. Now, in 2010, researchers who have
devoted years to working with these specific hESC lines are
understandingly hesitant to abandon this knowledge base in
order to pursue iPS research or cell reprogramming research.
Nor is it obvious that our society is better off if scientists cease
studying hESC lines, since future progress in the entire field will
benefit from the knowledge gained concerning embryonic stem
cell lines.
It is not surprising that individual states have sought to fill
the gap in available federal funding by acting strategically and
focusing on funding a narrow range of stem cell research. It is
logical to use specialization as a means of seeking the maximum
impact from limited dollars, because state governments lack the
resources of the federal government. Thus, California has
become a center of embryonic stem cell research while New
York has taken the lead in funding research using iPS cells.125
However, as states compete against each other for researchers,
seeking to attract top talent to relocate within their borders, the
current funding landscape creates an incentive to build off of
their existing subject area strengths rather than to seek a wide
variety of talent. The sorting of research focus among different
geographic areas will result in an entrepreneurial and
competitive market, where each state has an economic incentive
to pursue their chosen type of research and where private
companies will sort themselves geographically to parallel each
125. For example, the Empire State Stem Cell Board has awarded over $16
million in funds targeted to iPS and other non-embryonic derivation approaches to
stem cells. See Stem Cell Research Award Grantees, NEW YORK STATE DEP'T OF
HEALTH, http://www.nyhealth.gov/funding/targeted-and-generic awardlist.htm
(last revised March 2009). In New York, twenty-one percent of research grants have
gone to support hESC while in California fully seventy-five percent of research
grants have supported hESC research. See Karmali, supra note 89, at Table 1.
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state's specialization.126  This self-selection process feeds on
itself, and it is unlikely to reverse even if NIH funding continues.
Therefore, the current balkanized funding landscape is not
the optimum approach towards advancing stem cell science. In
particular, the current funding scheme is inferior to the
alternative of using the NIH as a single source of funding for all
types of stem cell research. However, now that several states
have invested in the facilities and other infrastructure involved
in setting up a funding mechanism separate from the NIH, it is
doubtful that these states will walk away from that investment.
It is too late to turn back the clock and attempt to re-centralize
funding at the federal level.
In an attempt to avoid the recurrence of similar funding
controversies in the future, some observers have suggested
placing the decision of whether to federally fund different kinds
of medical research exclusively in the hands of medical
researchers, thereby isolating these decisions from political
influence.127 However, this approach has been criticized on the
grounds that it fails to ensure democratic accountability and that
it effectively abandons ethical principles.128 In any event, it is
manifestly unrealistic to assume that politicians at either level-
state or federal-will relinquish their power to influence the
determination of public health policy.
The recognition that politicians have primacy of place in the
field of public bioethics is not the end of the matter, however.
While it may be useful to underscore the fundamental role that
our elected officials play in the determination of stem cell
funding policy, this observation does not lead to the conclusion
that these officials should be left with unbounded discretion. To
the contrary, when fulfilling their responsibility to formulate
funding policies for medical research, our elected
representatives should be guided by two objective and neutral
principles: 1) the federal government should be the preferred
126. See Noll, supra note 105, at 1169-70.
127. See Snead, supra note 1, at 1553-58.
128. Id. at 1604.
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source for funding basic medical research and 2) funding
decisions should not adopt one religious perspective over
another.
THE FEDERAL GOVERNMENT SHOULD BE THE PREFERRED SOURCE
OF FUNDING FOR BASIC MEDICAL RESEARCH
The freedom of scientific inquiry was one of the key
principles of the "American Enlightenment."129 Basic intellectual
themes advanced during the founding of our nation included
the right of free speech, the connection between an educated
citizenry and the possibility of self-government, and the
opposition to the Stamp Act on the grounds that it acted as an
economic barrier to the free circulation of ideas.13 0 The Founders
believed strongly in the value of "knowledge diffused
generally" among the people.'13 The belief that scientific inquiry
was a force for the benefit for all mankind was popularly held,
and found its embodiment in the persona of Benjamin
Franklin.132 Any restrictions on scientific progress, whether
imposed by governmental or clerical sources of authority, were
resisted strenuously. It is significant that the limited universe of
powers granted to the federal government under the
Constitution included the power to create a system for issuing
patents. The federal government created by the United States
Constitution was vested with its power by a people who
believed that public benefits flowed inevitably from creativity in
the sciences and the useful arts.'>
Support for medical research is consistent with this
traditional vision of the power of the federal government,
despite objections that have been raised concerning federal
regulation of the broader health care market. The question has
129. Id. at 1560-63.
130. See LEWIS HYDE, COMMON AS AIR: REVOLUTION, ART, AND OWNERSHIP 93-
100 (2010).
131. See id. at 95 (quoting John Adams).
132. See id. at 112-34.
133. See GORDON S. WOOD, THE RADICALISM OF THE AMERICAN REVOLUTION
191-92 (1991).
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arisen whether the federal government possesses the power
under the Commerce Clause of the Constitution to mandate the
purchase of private health insurance. Opponents of health care
reform argue that the Commerce Clause should be read to
circumscribe the power of the federal government to intervene
in the private market for health care insurance, often citing the
economist Friedrich Hayek in support of their views. However,
Hayek's caution against government overreaching in private
markets does not apply to the funding of basic research,1 4 and
Hayek himself was a strong supporter of free scientific
inquiry.135
Instead, the funding of stem cell research is best understood
as a modern manifestation of the federal government's
traditional use of general tax revenues to invest in industries
that contribute to the national infrastructure and that therefore
benefit the entire nation. Government support for new
technologies in the transportation and communication industries
134. As explained by Hayek:
All modem governments have made provision for the indigent,
unfortunate, and disabled and have concerned themselves with questions
of health and the dissemination of knowledge. There are common
needs that can be satisfied only by collective action and which can be thus
provided for without restricting individual liberty.... There is little reason
why the government should not also play some role, or even take the
initiative, in such areas as social insurance and education, or temporarily
subsidize certain experimental developments.
FRIEDRICH A. HAYEK, THE CONSTITUTION OF LIBERTY 257-58 (1960) (emphasis
added).
135. Id. at 404-05. Hayek wrote generally in support of scientific progress and
against government interference in the free dissemination of knowledge:
Personally, I find that the most objectionable feature of the conservative
attitude is its propensity to reject well-substantiated new knowledge
because it dislikes some of the consequences which seem to follow from it.
. . I will not deny that scientists as much as others are given to fads and
fashions and that we have much reason to be cautious in accepting the
conclusions that they draw from their latest theories. But the reasons for
our reluctance must themselves be rational and must be kept separate
from our regret that the new theories upset our cherished beliefs. I can
have little patience with those who oppose, for instance, the theory of
evolution or what are called 'mechanistic' explanations of the phenomena
of life simply because of certain moral consequences which at first seem to
follow from these theories, and still less with those who regard it as
irreverent or impious to ask certain questions at all.
Id.
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has long been accepted as a means of promoting economic
development. However, in the 21st century our nation's
economic growth is not driven by industries that produce and
ship tangible products. Instead, the fastest growing sectors of
the American economy are tied to intellectual advances in areas
such as biotechnology and telecommunications. The state of
California promoted its bond offering to fund the creation of
CIRM as a state investment in "intellectual capital." 36 In so
doing, California officials drew a parallel between government
investment in intellectual infrastructure in the sciences and the
traditional government financial support of physical
infrastructure such as roads and bridges.
The present universe of scientific knowledge is not static,
and the federal government plays an important role in funding
efforts to expand upon our current base of knowledge. The
federal government has greater resources than state
governments, it can generate greater economies of scale when
allocating research dollars among recipients, and, when it serves
as the primary source of research funding, the federal
government can avoid needless duplication of research efforts.
The role of the federal government is critical because it is
highly unlikely that the private market will fund the optimum
amount of basic medical research from a societal perspective.
Private industry is beholden to its shareholders, who demand a
return on their investment. This profit motive risks the creation
of "orphan diseases," instances where companies forego
research that is unlikely to lead to profitable applications due to
the small number of persons afflicted. Shareholders also possess
a short investment horizon, which creates a disincentive for
management to fund research where direct applications lie
decades in the future. 137 The federal government does not
136. See Treasurer Lockyer Urges Californians to Participate in First Stem Cell Bond
Issue: $250 Million Sale Makes State Leader in Embryonic Stem Cell Research, CAL. INST.
FOR REGIONAL MED. (Oct. 2, 2007), www.cirm.ca.gov/PressRelease_100207.
137. See Melissa Little et al., Delivering on the Promise of Human Stem-Cell
Research: What Are the Real Barriers?, 7 EuR. MOLECULAR BIOLOGY ORG. REP. 1188,
1190-91 (2006) (listing as impediments to private investment in the field skepticism
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operate within these constraints.
Without government funding, the pharmaceutical and
biotechnology industries will only serve the interests of those
with the most common afflictions, or the interests of those who
can afford expensive drugs and therapies. Low-income
populations, in particular, are vulnerable to being left out of a
market-driven system of medical research. In such cases, the
federal government should use its funding power to help ensure
that vital research continues and that the benefits of such
research are made available to all.
FUNDING DECISIONS SHOULD NOT ADOPT ONE RELIGIOUS
PERSPECTIVE OVER ANOTHER
Government policymakers must base their public health
decisions on non-religious grounds. The federal government
should not incorporate one particular religious point of view as
part of the official rationale for deciding whether or not to fund
medical research. To do so is to adopt one religious perspective
over another. There are a variety of religious perspectives on the
moral status of the embryo, and it would violate the
Constitution for any branch of government to endorse one
religious perspective on the issue over another.138
A respect for religious pluralism is one of the basic tenets of
over "the likely success of stem-cell research," the fear that consumers will associate
the company with a controversial topic, uncertainty over intellectual property
rights, a lack of experience with the FDA approval process in the context of stem
cells and doubts that any marketable products will ultimately result from the
science).
138. John Danforth, the former Republican Senator from Missouri and an
ordained Episcopal priest, concluded as much:
What distinguishes the opposition to embryonic stem cell research and
[therapeutic cloning] is that it is based solely on a religious belief that life
begins before implantation in the uterus. This religious concept is in
opposition to the convictions of other people of faith who do not share this
definition of the beginning of life, and who believe that it is their own
religious obligation to discover the cures for disease, to heal the sick, to
relieve suffering, and to save lives.
Legislators considering banning such research should realize that they are
being asked to establish one religious point of view and to oppose another.
DANFORTH, supra note 41, at 97.
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our constitutional system. It is well understood that the First
Amendment of the Constitution precludes the federal
government from establishing an official religion.139 However,
there is also strong evidence that the original language that
James Madison proposed for the First Amendment was intended
to go further and disestablish official religions at the state level
as well.140 Significantly, the First Amendment was designed to
protect freedom of conscience by preventing any one religious
sect from receiving a preferential place under the law.141 In fact,
the overall purpose of the First Amendment to the Constitution
was to ensure that all religious faiths were treated in a non-
preferential fashion by public officials.
One example of the Founders' concern over government
acts that granted preferential treatment to one religious
denomination over another is reflected in the early debate over
the constitutionality of the executive branch issuing prayer day
proclamations. While Presidents Washington and Adams had
issued proclamations declaring a "national day of prayer,"
President Jefferson considered such proclamations
unconstitutional under the First Amendment.142 James Madison
agreed with Jefferson, explaining his opposition on the grounds
that the public trust that is delegated to elected officials does not
include the agency to decide questions of religious faith.14 1
These basic principles continue to carry great weight today.
Recent Supreme Court precedent has employed the doctrine of
judicial review in order to police the separation of church and
state. The Court has emphasized that under the Constitution all
official government acts must have a rational basis beyond the
government's desire to adopt a moral point of view. In order to
139. WILLS, supra note 8, at 226-29.
140. Id. at 229-32. The language of the First Amendment that was ultimately
ratified did not directly speak to this point, and states would continue to support
established religions with tax dollars until Massachusetts abandoned the practice in
1833. See also DANIEL WALKER HOWE, WHAT HATH GOD WROUGHT: THE
TRANSFORMATION OF AMERICA, 1815-1848 164-65 (2007).
141. See WILLS, supra note 8, at 232-35.
142. Id. at 237.
143. Id. at 237-41.
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establish rational grounds for passing legislation, for example,
state legislators cannot rely solely on moral arguments that
condemn sodomy.144 The Supreme Court also struck down a
popularly ratified amendment to the Colorado State
Constitution on the grounds that it could only be defended as an
expression of animus against homosexuals that was premised
upon moral condemnation. 145 If, as expected, the Ninth Circuit
rules that California's prohibition on same sex marriage violates
the Constitution, it will be one consequence of the federal courts'
refusal to sanction official government policies that rest solely on
religious justifications.1 46
It has been argued that the government's refusal to accord
blastocysts donated for research the moral status of a "person"
would itself be a choice that promotes a religious perspective.
This argument mistakenly assumes that the federal government
is being asked to choose between a religious perspective and a
secular perspective, and that to choose secularism is the
equivalent of choosing a religious point of view. As discussed
above, the stem cell funding debate does not ask the government
to make a binary choice between, on the one hand, advancing
religion or advancing secularism on the other. Instead, the
government is being asked to choose among a variety of
different religious perspectives that view the beginning of
personhood as occurring at different stages. For the government
144. See Lawrence v. Texas, 539 U.S. 558, 578 (2003) (Kennedy, J.) (holding that
the Texas anti-sodomy statute "furthers no legitimate state interest which can
justify its intrusion into the personal and private life of the individual"). In the
same case, Justice O'Connor stated:
Moral disapproval of this group, like a bare desire to harm the group, is an
interest that is insufficient to satisfy rational basis review under the Equal
Protection Clause . . Indeed, we have never held that moral
disapproval, without any other asserted state interest, is a sufficient
rationale under the Equal Protection Clause to justify a law that
discriminates among groups of persons.
Id. at 582 (O'Connor, J., concurring).
145. See Romer v. Evans, 517 U.S. 620, 634 (1996).
146. See Perry v. Schwarzenegger, 704 F. Supp. 2d 921, 1001 (N.D. Cal. 2010),
cert. denied, 130 S. Ct. 2432 (stating that the "evidence shows conclusively that moral
and religious views form the only basis for a belief that same-sex couples are
different from opposite-sex couples").
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to remain neutral among these choices is not the same as the
government endorsing one perspective over another.
Government decisions that impact the funding of medical
research must be justifiable upon non-religious grounds.
CONCLUSION
Professor 0. Carter Snead has argued persuasively that, in
questions of public bioethics, publicly accountable elected
officials should be called to make the hard policy decisions
themselves rather than to delegate their decision-making
authority to panels of scientific experts.1'4 However, what is
missing from Professor Snead's analysis is the recognition that
these elected officials exercise a public trust. The defect in
Professor Snead's approach to public bioethics is that it
emphasizes the "bioethics" component of the term at the
expense of the "public" component. When making policy
decisions in the realm of public health, politicians must be able
to justify their choices on the basis of objective and neutral
principles.
The study of public bioethics is incomplete without a
recognition that the federal government operates within a
sphere of authority and under an obligation of pluralism that is
separate from the spheres of religion and the market economy.' 4 8
Within its proper sphere, the federal government has an
affirmative responsibility to foster the pursuit of knowledge, and
it lacks the capacity to adopt as its own one out of a competing
multitude of religious viewpoints. The Madisonian separation
of church and state is an integral part of the limited government
created under the United States Constitution, 149 and maintaining
that separation is an ethical good that our elected officials must
147. See Snead, supra note 1, at 1602.
148. See generally MICHAEL WALZER, SPHERES OF JUSTICE: A DEFENSE OF
PLURALISM AND EQUALITY 243-48 (1983) (Walzer argues that a free society consists
of separate spheres within which the state, the church, and corporations each
dominate, and where the polity acts to maintain the separation of the spheres.).
149. See generally WILLS, supra note 8, at 175-249 (tracing the intellectual
foundations of the separation of church and state under the Constitution).
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weigh along with other ethical goods such as the protection of
vulnerable populations and the promotion of justice.
The convergence of science, religion and politics in the
determination of public health policy presents a recurring
temptation for policymakers to adopt policies designed to curry
favor with distinct religious denominations rather than policies
based upon scientific and medical objectives. This danger is
heightened when the ever-changing state of scientific knowledge
allows elected officials to exploit uncertainties and conflicting
data when expressing the rationale for their position.
The federal government's slow response to the AIDS crisis
in the 1980s reflects one manifestation of this phenomenon.
Today, a common refrain among scientists engaged in stem cell
research is that the uncertain availability of federal funds for
hESC research over the past decade has slowed progress
towards translating basic science into cures, has deterred
graduate students and other researchers from entering the entire
field, and has jeopardized the United States' leadership position
in stem cell research versus our global competitors.5 0 If the stem
cell funding controversy provides any lessons for the future, it is
that the failure to follow objective and neutral principles when
making decisions for the public good inevitably undermines the
achievement of our society's objectives to extend lives and to
reduce suffering.
150. See Public Funding Impacts Progress of Human Embryonic Stem Cell Research,
SCIENCE DAILY (June 5, 2008), http://www.sciencedaily.com/releases/2008/06
/080604140945.htm.
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